SPOTLIGHT: Crucell forges pact with Sanofi


Crucell stands to gain $112 million in a new development pact with Sanofi Pasteur, which wants to use its antibodies for a rabies vaccine. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.